Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder

Brain Research Bulletin

Volumn 55, Issue 5, 2001, Pages 631-640

  Meador Woodruff, James H ^a   Hogg Jr, Alan J ^a   Smith, Robert E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AMPA receptors; Caudate; In situ hybridization; Kainate receptors; NMDA receptors; Nucleus accumbens; Putamen; Receptor autoradiography; Striatum

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; DIZOCILPINE; GLUTAMATE RECEPTOR; IFENPRODIL; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; AUTOPSY; BINDING SITE; BRAIN REGION; CORPUS STRIATUM; DEPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; PUTAMEN; SCHIZOPHRENIA;

ADULT; AGED; BIPOLAR DISORDER; CAUDATE NUCLEUS; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; LIGANDS; MALE; MIDDLE AGED; NEURONS; NUCLEUS ACCUMBENS; PUTAMEN; RADIOLIGAND ASSAY; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0035878137     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(01)00523-8     Document Type: Article

References (58)

1. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
2. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients
3. Stable transfection of the NMDAR1 subunit in Chinese hamster ovary cells fails to produce a functional N-methyl-D-aspartate receptor
4. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers
5. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit
6. Schizophrenia; A subcortical neurotransmitter imbalance syndrome?
7. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia; An open-label study
8. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
9. Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation of polyamines and protein kinase C
10. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
11. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia; A reverse transcriptase-polymerase chain reaction (RT-PCR) study
12. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia
13. 3H]AMPA binding in postmortem human brain from psychotic subjects and controls; Increases in caudate nucleus associated with suicide
14. Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor
15. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS
16. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
17. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia
18. Recombinant human NMDA homomeric NMDAR1 receptors expressed in mammalian cells form a high-affinity glycine antagonist binding site
19. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
20. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics
21. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
22. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition
23. Cloned glutamate receptors
24. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia
25. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
26. Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus
27. Recent advances in the phencyclidine model of schizophrenia
28. Amelioration of negative symptoms in schizophrenia by glycine
29. Differences in Ca2+ permeability of AMPA-type glutamate receptor channels in neocortical neurons caused by differential GluR-B subunit expression
30. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
31. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia
32. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
33. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans; Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
34. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
35. N-methyl-D-aspartate receptors; Different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents
36. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics
37. NMDA receptor function and human cognition; The effects of ketamine in healthy volunteers
38. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia
39. Glutamate receptor expression in schizophrenic brain
40. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine
41. Heteromeric NMDA receptors; Molecular and functional distinction of subtypes
42. Molecular diversity of glutamate receptors and implications for brain function
43. 3H]kainic acid binding in the prefrontal cortex in schizophrenia
44. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains
45. RNA editing of human kainate receptor subunits
46. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia
47. ARNA editing of the glutamate receptor subunits gluR2 and gluR6 in human brain tissue
48. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
49. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus
50. Block of the N-methyl-D-aspartate receptor by phencyclidine-like drugs is influenced by alternative splicing
51. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia
52. Rat gluR7 and a carboxy-terminal splice variant, gluR7b, are functional kainate receptor subunits with a low sensitivity to glutamate
53. The role of RNA editing in controlling glutamate receptor channel properties
54. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics; Evidence on reversible up-regulation by typical neuroleptics
55. Effect of RNA editing and subunit co-assembly on single-channel properties of recombinant kainate receptors
56. Single-channel properties of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit composition
57. The Stanley Foundation brain collection and Neuropathology Consortium
58. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients